Cefdinir

Brands of Cefdinir in Kenya

Akudinir® , Unosource Pharma Limited
Labnir® , Laboratory & Allied Ltd
Kefnir®, Glenmark


Cefdinir in Kenya : Prices, Brands, Cost, Where to buy
Cefdinir Chemical Structure

Mode of Action

As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.
Mechanism of Resistance
Resistance to cefdinir is primarily through hydrolysis by some β-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability. Cefdinir is inactive against most strains of Enterobacter spp., Pseudomonas spp., Enterococcus spp., penicillin-resistant streptococci, and methicillin-resistant staphylococci. β-lactamase negative, ampicillin-resistant (BLNAR) H. influenzae strains are typically non-susceptible to cefdinir.
Antimicrobial Activity
Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections
Gram-Positive Bacteria
Staphylococcus aureus (methicillin-susceptible strains only)
Streptococcus pneumoniae (penicillin-susceptible strains only)
Streptococcus pyogenes

Gram-Negative Bacteria

Haemophilus influenzae
Haemophilus parainfluenzae
Moraxella catarrhalis

DOSAGE AND ADMINISTRATION

Adults and Adolescents (Age 13 Years and Older)
Type of InfectionDosageDuration
   Community-Acquired Pneumonia300 mg q12h10 days
   Acute Exacerbations of Chronic Bronchitis300 mg q12h
or
600 mg q24h
5 to 10 days
10 days
   Acute Maxillary Sinusitis300 mg q12h
or
600 mg q24h
10 days
10 days
   Pharyngitis/Tonsillitis300 mg q12h
or
600 mg q24h
5 to 10 days
10 days
   Uncomplicated Skin and Skin Structure Infections300 mg q12h10 days

INDICATIONS:

  • Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains)
  • Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).
  • Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).
  • Pharyngitis/Tonsillitis caused by Streptococcus pyogenes
  • Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

CONTRAINDICATIONS

Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

ADVERSE REACTION

Allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, and agranulocytosis. Pseudomembranous colitis symptoms may begin during or after antibiotic treatment
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:


Cefdinir in Kenya
Cefdinir in Kenya
Cefdinir in Kenya
Cefdinir in Kenya

Clinical | Pharmacokinetic data


Pregnancy Category: B (No risk in non-human studies)
Routes of Administration: Oral
Bioavailability: 16% to 21% (dose-dependent)
Protein Binding: 60% to 70%
Metabolosim: Negligible
Onset of Action: Not Available
Elimination Half life: 1.7 ± 0.6 hours
Excretion: Kidney

Legal Status | Dosage forms & Strengths


Prescription Category:
Prescription Only Medicine
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:


Drug Indentifiers:

CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard


Drug Images

References/ Citation:




What was the patient being treated for
%d bloggers like this: